NOCTI Guide

Syphilis Was Planning a Comeback Tour. One Pill Canceled Half the Dates

A new Nature Health study of 78,560 gay and bisexual men links doxyPEP to far fewer syphilis and chlamydia cases. Here's who qualifies, the fine print, and what to do next.

October 30, 2026 · Updated October 29, 2026 at 5:59 PM PDT · 4 min read

Curly-haired man with stubble in a black tank top lit by warm orange light, on a NOCTI Your Care Your World cover

Nearly 3,000 Fewer Syphilis Cases. One Pill Got the Credit

Picture the least romantic text you'll ever get: "Hey, so... you might want to get tested." Now picture getting it a lot less often. That's roughly what just happened in Australia. A study published October 28 in the journal Nature Health tracked 78,560 gay and bisexual men through 29 sexual health services and high-caseload GP clinics from 2022 to 2025. After the country rolled out guidance on doxyPEP, syphilis diagnoses came in at 2,430. Without it, researchers had projected 5,403. That's nearly 3,000 fewer syphilis diagnoses than expected, about 55% lower. Chlamydia fell too, landing roughly 36% below projections. And the hero of this story isn't some shiny new miracle drug. It's an antibiotic dermatologists have been handing out for acne for decades.

Meet DoxyPEP, the Antibiotic With a 72-Hour Deadline

DoxyPEP is short for doxycycline post-exposure prophylaxis. Translation: one 200 mg dose of doxycycline, taken within 72 hours after S*X, to lower the odds that a bacterial STI moves in. The CDC has recommended it since 2024 for gay and bisexual men and trans women who've had syphilis, chlamydia or gonorrhea in the past 12 months. Your clinician writes the prescription, you keep it at home, and you take it after the fact. The limit is one dose in any 24 hours, no matter how eventful your weekend was. Think of it as the morning-after pill's nerdy cousin, built for bacteria. Weird concept? Sure. But the numbers are getting very hard to ignore.

“Knowledge is a better wingman than panic.” — NOCTI

Plot Twist: Gonorrhea Didn't Get the Memo

Here's where the Australian data gets spicy. Gonorrhea barely moved. Researchers counted 16,099 diagnoses against 14,543 projected, a difference that wasn't statistically significant. That lines up with what U.S. data already showed. In a 2025 study in JAMA Internal Medicine, more than 2,200 HIV PrEP users at Kaiser Permanente Northern California got doxyPEP in its first year. Among them, chlamydia dropped 79% and syphilis 80%. Gonorrhea? Just 12%. The CDC notes protection against gonorrhea was less consistent in trials, and some gonorrhea strains already resist this family of antibiotics. The biggest win went to the men who needed it most. Among guys diagnosed with an STI in the previous year, the Australian team found syphilis rates about 64% lower than projected. So doxyPEP is a star player. It's just not the whole team.

NOCTI's take: Stop Whispering About It. Ask for It.

Opinion time. Gay and bi men have done the homework on their own health for decades: PrEP, testing schedules, U=U, the group-chat explainers nobody else would write. DoxyPEP deserves the same energy, minus the shame. If you qualify and no one has brought it up, that's not a you problem. That's a system that still gets shy about men's sexual health. Bring it up first. A good clinician won't even blink. And to anyone already typing "free pass" in the comments: every prevention tool gets that accusation. Every single time, the better answer has been more information, not more shame.

The Fine Print Your Group Chat Skipped

Now the grown-up part. DoxyPEP targets bacterial STIs: syphilis, chlamydia and, less reliably, gonorrhea. It does nothing for HIV. PrEP, PEP and U=U still handle that job. The bigger worry is antibiotic resistance. The CDC says resistance and effects on the gut microbiome need ongoing monitoring, and long-term data are still missing. The Australian authors were careful too, describing their findings as "population-level associations" rather than proof of what the pill does for any one person. Side effects are usually mild but real: nausea, sun sensitivity and an irritated esophagus if you swallow it and lie down. The CDC advises a full glass of liquid, staying upright for an hour, and keeping the dose two hours away from dairy, antacids and supplements with calcium, iron or magnesium.

Your 5-Step Game Plan (No Spiraling Required)

The study's authors called doxyPEP "a promising complement to existing test-and-treat strategies." Complement is the magic word. Here's how to use it like a pro: 1. Check if you qualify. The CDC recommendation covers gay and bisexual men and trans women with a bacterial STI in the past 12 months. Outside that group, it's a conversation worth having with your clinician. 2. Ask for it by name. Say "doxyPEP" to your doctor, a sexual health clinic or your PrEP provider. Keep the prescription filled so the 72-hour window never closes on you. 3. Keep testing every 3 to 6 months. The CDC pairs doxyPEP with regular STI testing, HIV screening and a check-in on whether you still need it. 4. Keep your HIV plan separate. PrEP, PEP, condoms and U=U cover HIV. Doxy doesn't. 5. If a test comes back positive, breathe. Bacterial STIs are common, treatable and nothing to be ashamed of. Get treated, let recent partners know if you can, and get on with your week.

“Get tested, get informed, then get on with your life.” — NOCTI

The Takeaway: Prepared Is the New Hot

Protection isn't paranoia. It's confidence with a plan. Want men's health resources and independent professionals who get it, no awkward explaining required? Start at joinnocti.com/discover. This article is for general information and isn't medical advice.

SourcesNature Health, Bioengineer.org +2 more

Find men’s massage near you

Compare local providers privately and contact the professional you choose directly.

Search NOCTI